Birman P.

(Pascal Birman)

pegvisomant patient study igf 1 levels coadministration pegvisomant dose /week level treatment acromegaly endocrinology ef ﬁcacy normalization coadministration period period journal therapy ﬁcacy igf 1 z-score european journal combination therapy z-score european injection tumor size combination tumor run-in 60 mg /week response lanreotide pegvisomant monotherapy visit growth signi monotherapy safety month strasburger cj baseline p ﬁzer run-in period subject ipsen ﬁcant receptor somatostatin analog nondiabetic igf 1 somatostatin analogs responder serum autogel igf 1 level transaminase point www.eje-online.org change withdrawal antagonist /month effect octreotide herder ww k 0.6g value population symptom 40 mg novarti ﬁ rst janssen ja nondiabetic patients 60 mg feelders ra vance ml hormone percentage reduction

1 Most Recent Publications

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone (Article)
Lely, A.J. van der Bernabeu I. Cap J. Caron P. Colao, A. Marek J. Neggers, S.J.C.M.M. Birman P.

2011-03-01

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.